You are here
Australia is a developed nation with the world's fifth-highest per capita income. The country enjoys the second-highest human development index globally, and performs strongly in international comparisons of quality of life, health, education, and other measures. More than one quarter of Australians are born overseas.
- Multicultural population
- European 92%
- Asian 7%
- Aboriginal and other 1%
- Population concentrated around large regional cities
- English is the official language
- World renowned healthcare and clinical research environment
- History of medical research innovation and excellence
- High regulatory and ethical standards
With one of the world’s lowest birth rates and excellent medical care, Australia has a rapidly aging population. Smoking rates and mortality/morbidity associated with cardiovascular diseases have decreased, but the prevalence of obesity and diabetes is escalating. In 2012, 62.7% of adults were overweight or obese. Cancer is estimated to be the leading cause of burden of disease in Australia, accounting for approximately 19% of the total disease burden. High prevalence diseases include:
- Mental health
Clinical Trial Landscape
Australia is home to some of the world’s best medical researchers and health professionals and enjoys world-class research infrastructure. Clinical trial capability is of an international standard and the country is well suited to conduct complex early stage trials. Trials in Australia are generally focused on complex indications aligned with the standard of care in developed nations.
Clinical trials are regulated by the Therapeutic Goods Administration (TGA) and Local, Regional, or Multicenter IECs/IRBs.
The average timeline for IEC/IRB approval is ~2-4 months.
23 million people
89% reside in urban areas
99% literacy rate
- Novotech opened its first Australian contract research organisation office in 1996
Why choose Australia for clinical research?
There are many compelling reasons to consider Australian contract research organisations:
- High quality research and facilities
- State of the art equipment for testing, treatment and analysis
- Efficient ethics and regulatory framework via Clinical Trial Notification (CTN) scheme
- Diverse participant recruitment pool
- Investment incentives
- Off-season recruitment potential to northern hemisphere
- Fast set-up and approval times
- Robust intellectual property system
- Simple and efficient regulatory scheme.